Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 1
2009 1
2010 3
2011 3
2012 5
2013 5
2014 8
2015 2
2016 2
2017 3
2018 3
2019 3
2020 4
2021 8
2022 9
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Among authors: moins teisserenc h. Lancet. 2023 Jun 10;401(10392):1941-1950. doi: 10.1016/S0140-6736(23)00329-X. Epub 2023 Apr 24. Lancet. 2023. PMID: 37105210
Cutaneous manifestations of lymphoid-variant hypereosinophilic syndrome.
Laurent C, Lefèvre G, Kahn JE, Staumont-Salle D, Felten R, Puget M, Moulinet T, Machelart I, Launay D, Charvet E, Bouaziz JD, Jachiet M, Espitia A, Mahr A, Le Clech C, Malphettes M, Morice C, Mourah S, Moins-Teisserenc H, Lifermann F, Soulier-Guérin K, Villate A, Baillou C, Grados A, Robbins A, Abisror N, Bagot M, Boutboul D, Panel K, Vignon-Pennamen MD, Rivet J, Battistella M, Groh M, de Masson A; CEREO network. Laurent C, et al. Among authors: moins teisserenc h. Br J Dermatol. 2022 Dec;187(6):1011-1013. doi: 10.1111/bjd.21782. Epub 2022 Aug 12. Br J Dermatol. 2022. PMID: 35862277 Free PMC article.
Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
de Masson A, Darbord D, Dobos G, Boisson M, Roelens M, Ram-Wolff C, Cassius C, Le Buanec H, de la Grange P, Jouenne F, Louveau B, Sadoux A, Bouaziz JD, Marie-Cardine A, Bagot M, Moins-Teisserenc H, Mourah S, Battistella M. de Masson A, et al. Among authors: moins teisserenc h. Blood. 2022 Mar 24;139(12):1820-1832. doi: 10.1182/blood.2021013341. Blood. 2022. PMID: 34905599 Free article.
CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas.
Ta VA, Battistella M, Zhao LP, Dobos G, Ram-Wolff C, Madelaine I, Bories JC, Tournilhac O, Rouanet J, Veyrat-Masson R, Bouaziz JD, Marie-Cardine A, Bagot M, Bensussan A, Moins-Teisserenc H, De Masson A. Ta VA, et al. Among authors: moins teisserenc h. J Invest Dermatol. 2023 Jul;143(7):1329-1332.e3. doi: 10.1016/j.jid.2023.01.009. Epub 2023 Jan 28. J Invest Dermatol. 2023. PMID: 36716922 No abstract available.
Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas.
Giustiniani J, Ta VA, Belkhelouat S, Battistella M, Ouahbi D, Ram-Wolff C, Louveau B, Mourah S, Bagot M, Moins-Teisserenc H, Ortonne N, Bensussan A, De Masson A. Giustiniani J, et al. Among authors: moins teisserenc h. J Invest Dermatol. 2024 Mar 28:S0022-202X(24)00259-8. doi: 10.1016/j.jid.2024.03.019. Online ahead of print. J Invest Dermatol. 2024. PMID: 38555062 Free article. No abstract available.
CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.
Giustiniani J, Dobos G, Moins-Teisserenc H, Eustaquio T, Battistella M, Ortonne N, Ram-Wolff C, Bouaziz JD, Marie-Cardine A, Mourah S, Bagot M, Kupper TS, Clark RA, Bensussan A, de Masson A. Giustiniani J, et al. Among authors: moins teisserenc h. Blood Adv. 2022 Jun 14;6(11):3507-3512. doi: 10.1182/bloodadvances.2021006512. Blood Adv. 2022. PMID: 35201316 Free PMC article. No abstract available.
Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides.
Wang J, Ram-Wolff C, Dobos G, Al Hage J, Grange F, Rivet J, Vignon-Pennamen MD, Moins-Teisserenc H, Boisson M, Moegle C, Sadoux A, Mourah S, Battistella M, Bagot M, de Masson A. Wang J, et al. Among authors: moins teisserenc h. Br J Dermatol. 2022 Jul;187(1):129-131. doi: 10.1111/bjd.21030. Epub 2022 Apr 7. Br J Dermatol. 2022. PMID: 35083741 No abstract available.
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M. Leupin N, et al. Among authors: moins teisserenc h. Cancer. 2022 Mar 1;128(5):1004-1014. doi: 10.1002/cncr.34005. Epub 2021 Nov 2. Cancer. 2022. PMID: 34726773 Free article. Clinical Trial.
Graft-versus-lymphoma effect in skin after allogeneic hematopoietic stem cell transplantation for Sézary syndrome.
Ranjbaryan M, Calvani J, Louveau B, Cuccuini W, Battesti G, Bozonnat A, Moins-Teisserenc H, Michonneau D, Bagot M, Ram-Wolff C, Dobos G, Mourah S, Battistella M, de Masson A. Ranjbaryan M, et al. Among authors: moins teisserenc h. Eur J Dermatol. 2023 Aug 1;33(4):439-440. doi: 10.1684/ejd.2023.4522. Eur J Dermatol. 2023. PMID: 37823502 No abstract available.
62 results